Current and historical daily PE Ratio for Cyclacel Pharmaceuticals Inc (
) from 2010 to Jun 06 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Cyclacel Pharmaceuticals stock (STU:UXI) PE ratio as of Jun 06 2024 is 0.
More Details
Cyclacel Pharmaceuticals Inc (STU:UXI) PE Ratio (TTM) Chart
Cyclacel Pharmaceuticals Inc (STU:UXI) PE Ratio (TTM) Historical Data
View and export this data going back to 2010. Start your Free Trial
Total 1283
- 1
- 2
- 3
- 4
- 5
- 6
- 15
| Cyclacel Pharmaceuticals PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-06 | At Loss | 2024-04-03 | At Loss |
| 2024-06-05 | At Loss | 2024-04-02 | At Loss |
| 2024-06-04 | At Loss | 2024-03-28 | At Loss |
| 2024-06-03 | At Loss | 2024-03-27 | At Loss |
| 2024-05-31 | At Loss | 2024-03-26 | At Loss |
| 2024-05-30 | At Loss | 2024-03-25 | At Loss |
| 2024-05-29 | At Loss | 2024-03-22 | At Loss |
| 2024-05-28 | At Loss | 2024-03-21 | At Loss |
| 2024-05-27 | At Loss | 2024-03-20 | At Loss |
| 2024-05-24 | At Loss | 2024-03-19 | At Loss |
| 2024-05-23 | At Loss | 2024-03-18 | At Loss |
| 2024-05-22 | At Loss | 2024-03-15 | At Loss |
| 2024-05-21 | At Loss | 2024-03-14 | At Loss |
| 2024-05-20 | At Loss | 2024-03-13 | At Loss |
| 2024-05-17 | At Loss | 2024-03-12 | At Loss |
| 2024-05-16 | At Loss | 2024-03-11 | At Loss |
| 2024-05-15 | At Loss | 2024-03-08 | At Loss |
| 2024-05-14 | At Loss | 2024-03-07 | At Loss |
| 2024-05-13 | At Loss | 2024-03-06 | At Loss |
| 2024-05-10 | At Loss | 2024-03-05 | At Loss |
| 2024-05-09 | At Loss | 2024-03-04 | At Loss |
| 2024-05-08 | At Loss | 2024-03-01 | At Loss |
| 2024-05-07 | At Loss | 2024-02-29 | At Loss |
| 2024-05-06 | At Loss | 2024-02-28 | At Loss |
| 2024-05-03 | At Loss | 2024-02-27 | At Loss |
| 2024-05-02 | At Loss | 2024-02-26 | At Loss |
| 2024-04-30 | At Loss | 2024-02-23 | At Loss |
| 2024-04-29 | At Loss | 2024-02-22 | At Loss |
| 2024-04-26 | At Loss | 2024-02-21 | At Loss |
| 2024-04-25 | At Loss | 2024-02-20 | At Loss |
| 2024-04-24 | At Loss | 2024-02-19 | At Loss |
| 2024-04-23 | At Loss | 2024-02-16 | At Loss |
| 2024-04-22 | At Loss | 2024-02-15 | At Loss |
| 2024-04-19 | At Loss | 2024-02-14 | At Loss |
| 2024-04-18 | At Loss | 2024-02-13 | At Loss |
| 2024-04-17 | At Loss | 2024-02-12 | At Loss |
| 2024-04-16 | At Loss | 2024-02-09 | At Loss |
| 2024-04-15 | At Loss | 2024-02-08 | At Loss |
| 2024-04-12 | At Loss | 2024-02-07 | At Loss |
| 2024-04-11 | At Loss | 2024-02-06 | At Loss |
| 2024-04-10 | At Loss | 2024-02-05 | At Loss |
| 2024-04-09 | At Loss | 2024-02-02 | At Loss |
| 2024-04-08 | At Loss | 2024-02-01 | At Loss |
| 2024-04-05 | At Loss | 2024-01-31 | At Loss |
| 2024-04-04 | At Loss | 2024-01-30 | At Loss |
Cyclacel Pharmaceuticals Inc (STU:UXI) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Cyclacel Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US23254L4059
Description
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers